Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections

Rhea-AI Filing Summary

Intensity Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held via live webcast. A total of 1,079,494 shares of common stock, representing approximately 40.74% of shares entitled to vote, were present, establishing a quorum.

Stockholders elected Dr. Emer Leahy and Lewis H. Bender as Class III directors to serve until the 2029 annual meeting. They also ratified EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Stockholders approved an amendment to the 2021 Stock Incentive Plan to add 150,000 shares and an amendment to the 2024 Employee Stock Purchase Plan to add 25,000 shares for issuance. They further approved the potential adjournment of the meeting, if necessary, to solicit additional proxies on the listed proposals.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares represented: 1,079,494 shares Quorum percentage: 40.74% Plan share increase: 150,000 shares +3 more

6 metrics

Shares represented 1,079,494 shares Shares present at 2026 annual meeting, representing quorum

Quorum percentage 40.74% Percentage of outstanding common shares entitled to vote represented

Plan share increase 150,000 shares Additional shares for 2021 Stock Incentive Plan approved by stockholders

ESPP share increase 25,000 shares Additional shares for 2024 Employee Stock Purchase Plan approved

Auditor ratification votes for 1,024,971 votes Votes in favor of ratifying EisnerAmper LLP for 2026

Adjournment approval votes for 939,304 votes Votes in favor of potential adjournment of the 2026 annual meeting

Key Terms

broker non-votes, emerging growth company, 2021 Stock Incentive Plan, 2024 Employee Stock Purchase Plan, +1 more

5 terms

broker non-votes financial

"Nominee | For | Withheld | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company regulatory

"Emerging growth company x"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

2021 Stock Incentive Plan financial

"approved an amendment to the Company’s 2021 Stock Incentive Plan"

2024 Employee Stock Purchase Plan financial

"amendment to the Company’s 2024 Employee Stock Purchase Plan"

independent registered public accounting firm financial

"as the independent registered public accounting firm of the Company"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001567264FALSE00015672642026-06-162026-06-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

Intensity Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41109

46-1488089

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1 Enterprise Drive, Suite 430 Shelton, CT						06484-4779
(Address of Principal Executive Offices)						(Zip Code)

(203) 221-7381

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:

Trading Symbol(s):

Name of Exchange on Which Registered:

Common Stock, $0.0001 par value per share

INTS

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2026, Intensity Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting") via live webcast. At the Annual Meeting, 1,079,494 shares of common stock, or approximately 40.74% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum.

At the Annual Meeting, the stockholders of the Company voted as set forth below on five proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026. The final voting results for each matter submitted to a vote of the Company’s stockholders are as follows:

Proposal 1. Election of Directors.

The election of two Class III directors, to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected and qualified.

Nominee			For			Withheld			Broker Non-Votes
Dr. Emer Leahy			416,613			19,465			643,416
Lewis H. Bender			422,149			13,929			643,416

Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm.

The ratification of the selection by the audit committee of the board of directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

For						Against						Abstain
1,024,971						4,852						49,671

Proposal 3. Approval of Amendment to 2021 Stock Incentive Plan.

The Company’s stockholders approved an amendment to the Company’s 2021 Stock Incentive Plan (the “Plan”) to increase the number of shares of common stock available for sale under the Plan by 150,000.

For						Against						Abstain						Broker Non-Votes
363,563						69,252						3,263						643,416

Proposal 4. Approval of Amendment to 2024 Employee Stock Purchase Plan.

The Company’s stockholders approved an amendment to the Company’s 2024 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares of common stock available for sale under the ESPP by 25,000.

For						Against						Abstain						Broker Non-Votes
407,404						25,350						3,324						643,416

Proposal 5. Approval of any Postponement or Adjournment of 2026 Annual Meeting, If Necessary.

The Company’s Stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.

For						Against						Abstain
939,304						126,814						13,376

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 16, 2026

			Intensity Therapeutics, Inc.
			By:			/s/ Lewis H. Bender
						Name:			Lewis H. Bender
						Title:			Chief Executive Officer

FAQ

What did Intensity Therapeutics (INTS) stockholders approve at the 2026 annual meeting?

Stockholders re-elected two Class III directors, ratified EisnerAmper LLP as auditor for 2026, approved share increases under the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan, and authorized a potential adjournment of the meeting to solicit additional proxies on these proposals.

How many Intensity Therapeutics (INTS) shares were represented at the 2026 annual meeting?

A total of 1,079,494 shares of Intensity Therapeutics common stock were represented at the meeting, equal to approximately 40.74% of the outstanding shares entitled to vote, which was sufficient to establish a quorum for conducting the company’s official business and voting on all proposals.

Which directors were elected at Intensity Therapeutics’ 2026 stockholder meeting?

Stockholders elected Dr. Emer Leahy and Lewis H. Bender as Class III directors. They will serve until the 2029 annual meeting of stockholders, or until their successors are elected and qualified, based on the final voting results reported in the meeting outcomes.

What changes were made to Intensity Therapeutics’ 2021 Stock Incentive Plan?

Stockholders approved an amendment to the 2021 Stock Incentive Plan, increasing the number of shares of common stock available for issuance under the plan by 150,000 shares. This expansion supports future equity-based compensation and incentive awards for eligible participants in the company’s programs.

How was Intensity Therapeutics’ 2024 Employee Stock Purchase Plan amended?

The 2024 Employee Stock Purchase Plan was amended to increase the shares of common stock available for sale under the plan by 25,000. This approval allows more employee participation in share purchases through the ESPP structure authorized by the company’s stockholders.

Who will audit Intensity Therapeutics’ financials for the year ending December 31, 2026?

EisnerAmper LLP will serve as Intensity Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026, after stockholders voted to ratify its selection by the board’s audit committee at the 2026 annual stockholder meeting.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB